contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


magle-group-completes-european-medical-device-filing-for-the-use-of-emboceptr-s-in-genicular-artery-embolisation

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed, a contract development and manufacturing organization (CDMO). Magle PharmaCept, an established sales and marketing company for the development and direct sales of the Groups medical technology products, and Magle Biopolymers A/S, a specialized manufacturing organization of Dextran technology.

Magle Chemoswed Holding

Magle Group today announces that it has successfully completed its European medical device filing to extend the clinical use of EmboCept® S, the company’s proprietary degradable starch microsphere...

<div class="mfn-preamble"><p><strong>Magle Group today announces that it has successfully completed its European medical device filing to extend the clinical use of EmboCept® S, the company’s proprietary degradable starch microsphere (DSM) technology, for Genicular Artery Embolisation (GAE).</strong></p></div><div class="mfn-body"><p>GAE is a minimally invasive interventional radiology procedure used to treat&nbsp;symptomatic knee osteoarthritis&nbsp;by selectively reducing abnormal blood flow in the genicular arteries. The procedure provides a non-surgical treatment option for patients who have not responded to conservative management and offers meaningful improvements in pain and mobility.</p><p>EmboCept® S, already CE-marked for certain HCC embolisation procedures, it is designed to provide controlled, predictable, and fully degradable vessel occlusion. Extending its use to GAE further strengthens its position as a safe and versatile embolic across multiple therapeutic areas.</p><p>The filing submitted today begins the formal assessment under the European Medical Device Regulation (MDR 2017/745). The process involves a review of updated technical documentation and clinical evidence by Magle’s Notified Body to confirm that the expanded intended use is adequately supported. Once approved, GAE will be added as an authorised indication for EmboCept® S across Europe.</p><p>“Today’s submission marks a significant step in expanding the impact of EmboCept® S. Genicular Artery Embolisation represents an important therapeutic option for patients with knee osteoarthritis, and our degradable DSM technology is well suited to support physicians performing this procedure. This filing reflects the strength of our evidence generation and our commitment to advancing innovative care for patients,”&nbsp;said&nbsp;Helena Ossmer Thedius, Chief Innovation &amp; Marketing Officer at Magle Group.</p></div><div class="mfn-footer mfn-6592d21ec2a5"><p><strong class="mfn-heading-1">Contacts</strong></p><hr><p>Justin Pierce, CEO, phone +46 (0)70 593 58 21, <a rel="noopener" href="mailto:justin.pierce@maglechemoswed.com">justin.pierce@maglechemoswed.com</a> </p></div><div class="mfn-footer mfn-about mfn-70935ab259f1"><p><strong class="mfn-heading-1">About Us</strong></p><hr><p>The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Magle Biopolymers A/S- a specialized manufacturing organization of Dextran technology. Learn more on&nbsp;<strong><a rel="noopener" href="http://www.maglechemoswed.com/">www.maglechemoswed.com</a></strong> and <strong><a rel="noopener" href="https://maglegroup.com/">www.maglegroup.com</a></strong><strong> </strong>and <strong><a rel="noopener" href="http://www.maglepharmacept.com">www.maglepharmacept.com</a></strong><strong> </strong>and <strong><a rel="noopener" href="https://maglebiopolymers.com/">www.maglebiopolymers.com</a></strong></p><p>Vator Securities is the Company's certified adviser on Nasdaq First North Growth Market and can be reached at <a rel="noopener" href="mailto:ca@vatorsec.se">ca@vatorsec.se</a> or +46 (0)8-580 065 99.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/0adacaa4-651f-4dbc-9244-9f668a09583a/magle-group-completes-european-medical-device-filing-for-the-use-of-embocept-r-s-in-genicular-artery-embolisation.pdf" class="mfn-generated mfn-primary">Magle Group Completes European Medical Device Filing for the Use of EmboCept® S in Genicular Artery Embolisation</a></p></div>

Magle Group Completes European Medical Device Filing for the Use of EmboCept® S in Genicular Artery Embolisation